TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - MODERNA | Market Closed - Deutsche Boerse AG 03:37:22 2024-06-10 pm EDT | ||
| 7.54 EUR | +3.29% |
|
| Current month | -9.54% | ||
| 1 month | -27.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 7.54 | +3.29% |
| 24-06-07 | 7.3 | +4.29% |
| 24-06-06 | 7 | -0.99% |
| 24-06-05 | 7.07 | -10.28% |
| 24-06-04 | 7.88 | +4.10% |
Delayed Quote Deutsche Boerse AG
Last update June 10, 2024 at 03:37 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SH4SZ2 |
| ISIN | DE000SH4SZ23 |
| Date issued | 2022-01-11 |
| Strike | 228.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.38 € |
|---|---|
| Lowest since issue | 1 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
151
USD
Average target price
143.9
USD
Spread / Average Target
-4.68%
- Stock Market
- Certificates
- Certificat
